The global lyme disease treatment market size is expected to hit around US$ 3 billion by 2030 from at US$ 1.6 billion in 2020, expanding growth at a CAGR of 5.9% from 2021 to 2030.
The global lyme disease treatment market size is expected to hit around US$ 3 billion by 2030 from at US$ 1.6 billion in 2020, expanding growth at a CAGR of 5.9% from 2021 to 2030.
Lyme disease is the most common vector-borne disease. Climate is one of the many important factors that influences the transmission, distribution, and incidence of Lyme disease. Additionally, climate change leads to rise in the survival and activity period of ticks, and increases in the potential risk of Lyme disease. Other factors that affect the number of Lyme disease cases are changes in the population of host species (particularly deer), which affect tick population size.
Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/38527
The incidence of Lyme disease in the U.S. has nearly doubled since 1991, from 3.74 reported cases per 100,000 people to 7.95 reported cases per 100,000 in 2014. According to the Centers for Disease Control and Prevention, 20,000 to 30,000 confirmed cases of Lyme disease have been reported in the U.S. per year. Lyme disease is most common in New Hampshire, Maine, and Vermont, which have experienced the largest increase in reported case rates since 1991.
According to the World Health Organization, the number of cases in Europe has increased steadily; more than 360,000 cases having been reported over the past two decades. According to the Westgate Pet Clinic, 5% to 15% canines are infected by Lyme disease. Hence, rise in prevalence of Lyme disease in both animals and humans is anticipated to boost the growth of the global market.
Report Scope
In terms of test type, the global Lyme disease treatment market has been bifurcated into medication and tick removal. The medication segment is expected to dominate the global Lyme disease treatment market from 2021 to 2030. A range of FDA-approved medications such as antibiotics and NSAIDs are available to treat the early stage Lyme disease. This drives the segment. The antibiotics sub-segment is projected to lead the medication segment during the forecast period. Patients with Lyme disease usually recover rapidly and completely with appropriate antibiotics in the early stages. This contributes to the growth of the sub-segment. Cephalosporin, tetracycline, and macrolides antibiotics are commonly prescribed for the treatment of Lyme disease.
Based on route of administration, the global Lyme disease treatment market has been divided into oral, injectable, and topical. The oral segment is likely to grow at a higher CAGR from 2021 to 2031. The availability of products administered through oral route is projected to drive the segment. Physicians recommend doxycycline as the preferred agent for oral treatment of Lyme disease, due to its activity against other tick-borne illnesses.
In terms of distribution channel, the global Lyme disease treatment market has been classified into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment is projected to lead the global Lyme disease treatment market during the forecast period. The preference for distribution through retail pharmacy is anticipated to propel the segment.
Based on Region, North America is expected to account for a significant share of the global Lyme disease treatment market during the forecast period. The growth of the Lyme disease treatment market in the region can be attributed to rise in access to healthcare and increase in incidence of Lyme disease.
The market in Asia Pacific is likely to expand at a high CAGR from 2021 to 2030. The emergence of vector borne diseases in the region is projected to boost the growth of the market in the region. An article published in the National Library of Medicine stated that the prevalence rate of Lyme disease in northeast China was 1% to 4%. Moreover, rise in awareness about emerging tick-borne pathogens is anticipated to fuel the growth of the global market over the next few years.
Key Players
The report provides profiles of leading players operating in the global Lyme disease treatment market. These include GlaxoSmithKline plc, Pfizer, Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Almirall, LLC, Mayne Pharma, BoehringerIngelheim International GmbH, Galderma Laboratories, L.P., Lupin Pharmaceuticals, Inc., Chartwell Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Orion Corporation, and Amneal Pharmaceuticals LLC.
Market Segmentation
By Treatment Type
- Medication
-
- Antibiotics
- Cephalosporin
- Tetracycline
- Macrolides
- Others
- NSAID
- Others
- Antibiotics
-
- Tick Removal
By Type of Bacteria
-
- Borreliaburgdorferi
- Borreliamayonii
- Borreliaafzelii
- Borreliagarinii
- Others
By Route of Administration
-
- Oral
- Injectable
- Topic
By Application
-
- Humans
- Animals
By Distribution Channel
-
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
-
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Click Here to View Full Report Table of Contents
Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38527
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333